Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Wilms Tumor 6Ovarian Neoplasms 6Neuroblastoma 5Testicular Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Osteosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Kidney Neoplasms 4Astrocytoma 4Optic Nerve Glioma 3Oligodendroglioma 3Glioma 3Familial ependymoma 3Choroid Plexus Neoplasms 3Central Nervous System Neoplasms 3Testicular Germ Cell Tumor 2Teratoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Ovarian Germ Cell Cancer 2Neoplasms 2Liver Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors 1

Interventions

Erlotinib Hydrochloride 2Bevacizumab 2spartalizumab 1pamiparib 1atezolizumab 1Temozolomide 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Everolimus 1Disulfides 1Contrast Media 1Botulinum Toxins, Type A 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary leiomyomatosis and renal cell cancer × Temozolomide × Genitourinary × Clear all
NCT04603365 2023-05-17

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡